PH 50E

Drug Profile

PH 50E

Latest Information Update: 09 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pherin Pharmaceuticals
  • Developer Janssen L.P.; Pherin Pharmaceuticals
  • Class Anxiolytics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders

Most Recent Events

  • 09 Dec 2003 No development reported - Preclinical for Anxiety disorders in USA (Intranasal)
  • 15 Nov 2000 New profile
  • 15 Nov 2000 Preclinical development for Anxiety disorders in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top